Semaglutide: A Comprehensive Look at Both the Benefits and the Risks
Semaglutide offers broad benefits for diabetes, weight loss, and cardiovascular health but carries risks including pancreatitis and anesthetic complications.
Quick Facts
What This Study Found
Semaglutide provides multi-system benefits (glycemic control, weight loss, cardiovascular protection, potential neuroprotection) but carries risks including pancreatitis and anesthetic complications.
Key Numbers
Reviews oral and SC semaglutide. Covers glycemic control, weight loss, cardiovascular risk reduction, potential for Alzheimer disease and PCOS. Risks: pancreatitis, aspiration, AKI, gallbladder, NAION, diabetic retinopathy.
How They Did This
Comprehensive narrative review of clinical evidence on semaglutide's mechanisms, benefits, and adverse effects.
Why This Research Matters
With millions now taking semaglutide, both patients and providers need a balanced understanding of its risk-benefit profile.
The Bigger Picture
As semaglutide use expands beyond diabetes into obesity, neurodegeneration, and reproductive health, understanding its full safety profile becomes increasingly critical.
What This Study Doesn't Tell Us
Narrative review — does not systematically weight evidence quality. Some potential benefits (Alzheimer's, PCOS) are still early-stage.
Questions This Raises
- ?How should anesthesiologists manage patients on semaglutide before surgery?
- ?Do the benefits of long-term semaglutide use outweigh cumulative risks?
Trust & Context
- Key Stat:
- Double-edged sword Semaglutide offers significant metabolic and cardiovascular benefits but carries notable risks
- Evidence Grade:
- Narrative review synthesizing diverse clinical evidence — useful overview but evidence quality varies by indication.
- Study Age:
- Published in 2025, capturing current understanding of semaglutide's evolving therapeutic profile.
- Original Title:
- Semaglutide: Double-edged Sword with Risks and Benefits.
- Published In:
- Archives of internal medicine research, 8(1), 1-13 (2025)
- Authors:
- Pillarisetti, Lekha, Agrawal, Devendra K
- Database ID:
- RPEP-13055
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
What are the main risks of semaglutide?
Key risks include acute pancreatitis, pulmonary aspiration during anesthesia, gastrointestinal side effects, and various drug interactions.
Can semaglutide help with conditions beyond diabetes?
Emerging evidence suggests potential benefits for Alzheimer's disease and PCOS, though these uses are still investigational.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13055APA
Pillarisetti, Lekha; Agrawal, Devendra K. (2025). Semaglutide: Double-edged Sword with Risks and Benefits.. Archives of internal medicine research, 8(1), 1-13. https://doi.org/10.26502/aimr.0189
MLA
Pillarisetti, Lekha, et al. "Semaglutide: Double-edged Sword with Risks and Benefits.." Archives of internal medicine research, 2025. https://doi.org/10.26502/aimr.0189
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide: Double-edged Sword with Risks and Benefits." RPEP-13055. Retrieved from https://rethinkpeptides.com/research/pillarisetti-2025-semaglutide-doubleedged-sword-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.